Patents Assigned to Laboratoires Serono SA
-
Publication number: 20080200463Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: May 24, 2006Publication date: August 21, 2008Applicant: LABORATOIRES SERONO SAInventors: Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
-
Publication number: 20080188531Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: May 24, 2006Publication date: August 7, 2008Applicant: LABORATOIRES SERONO SAInventors: Anna Quattropani, Jerome Dorbais, David Covini, Gwenaelle Desforges, Thomas Rueckle
-
Patent number: 7402303Abstract: Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.Type: GrantFiled: October 3, 2001Date of Patent: July 22, 2008Assignee: Laboratoires Serono SAInventors: Amanda Proudfoot, Timothy N. C. Wells, Marie Kosco-Vilbois
-
Patent number: 7393660Abstract: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.Type: GrantFiled: December 21, 2004Date of Patent: July 1, 2008Assignee: Laboratoires Serono SAInventors: Christine Power, Amanda Proudfoot, Achim Frauenschuh
-
Publication number: 20080107621Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.Type: ApplicationFiled: August 30, 2005Publication date: May 8, 2008Applicants: APPLIED RESEARCH SYSTEMS ARS HOLDING S.A., LABORATOIRES SERONO SAInventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
-
Patent number: 7365225Abstract: The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs.Type: GrantFiled: July 20, 2004Date of Patent: April 29, 2008Assignee: Laboratoires Serono SAInventors: Russel J. Thomas, Dominique Swinnen, Jean-Francois Pons, Agnes Bombrun
-
Patent number: 7341995Abstract: The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.Type: GrantFiled: November 30, 2001Date of Patent: March 11, 2008Assignee: Laboratoires Serono SAInventors: Christine Plater-Zyberk, Christine Power, Jacques Colinge
-
Patent number: 7338653Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: May 6, 2005Date of Patent: March 4, 2008Assignee: Laboratoires Serono SAInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 7335680Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.Type: GrantFiled: December 19, 2002Date of Patent: February 26, 2008Assignee: Laboratoires Serono SAInventors: Yihua Liao, Zhong Zhao, Gian Luca Araldi
-
Patent number: 7335350Abstract: The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1?, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.Type: GrantFiled: March 31, 2003Date of Patent: February 26, 2008Assignee: Laboratoires Serono SAInventors: Amanda Proudfoot, Marie Kosco-Vilbois, Timothy Wells
-
Patent number: 7326411Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: March 7, 2005Date of Patent: February 5, 2008Assignee: Laboratoires Serono SAInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 7312358Abstract: The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor.Type: GrantFiled: October 15, 2001Date of Patent: December 25, 2007Assignee: Laboratoires Serono SAInventors: Anna Quattropani, Matthias Schwarz, Catherine Joran-Lebrun, Dennis Church, Alexander Scheer
-
Patent number: 7297099Abstract: The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.Type: GrantFiled: November 5, 2004Date of Patent: November 20, 2007Assignee: Laboratoires Serono SAInventors: Ursula Boschert, Georg Feger, Raghuram Selvaraju, Lilia Bernasconi, Ruben Papoian
-
Patent number: 7297777Abstract: A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified hCG obtained form the process is particularly high, amounting to about 25,000 IU/mg.Type: GrantFiled: January 22, 2001Date of Patent: November 20, 2007Assignee: Laboratoires Serono SAInventors: Gianfranco Paradisi, Mara Rossi, Laura Scaglia
-
Patent number: 7291593Abstract: The present invention relates to the use of FSH and/or a biologically-active analogue thereof in the production of a medicament for the treatment of infertility in women. The medicament is for administration at an initial dose in the range of from 100 to 600 IU followed by a second dose at least 3 days later in the stimulation phase. In one embodiment, the medicament is for administration of a dose in the range of from 300 to 600 IU on every third day of the first 6 days of the stimulation phase. In another embodiment, the initial dose is in the range of from 100 to 500 IU, with the second dose being administered between three and six, preferably four, days after the initial dose.Type: GrantFiled: January 9, 2001Date of Patent: November 6, 2007Assignee: Laboratoires Serono SAInventors: Louise Duerr-Myers, Ernest Loumaye
-
Patent number: 7291339Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to ? subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: December 1, 2003Date of Patent: November 6, 2007Assignee: Laboratoires Serono SAInventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel